Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (73 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 31 Dec 2024 – 20 Aug 2026, limited by Edelweiss BSE Capital Markets & Insurance ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Edelweiss BSE Capital Markets & Insurance ETF | Nifty 500 |
|---|---|---|
| 31 Dec 2024 | ₹100.00 | ₹100.00 |
| 19 Feb 2025 | ₹87.85 | ₹92.65 |
| 10 Apr 2025 | ₹89.11 | ₹90.98 |
| 29 May 2025 | ₹106.88 | ₹102.17 |
| 18 Jul 2025 | ₹112.91 | ₹104.02 |
| 06 Sep 2025 | ₹108.48 | ₹102.03 |
| 26 Oct 2025 | ₹113.58 | ₹105.86 |
| 14 Dec 2025 | ₹115.40 | ₹106.04 |
| 02 Feb 2026 | ₹111.84 | ₹102.06 |
| 24 Mar 2026 | ₹104.64 | ₹94.15 |
| 13 May 2026 | ₹115.74 | ₹100.01 |
| 01 Jul 2026 | ₹117.36 | ₹103.29 |
| 20 Aug 2026 | ₹115.73 | ₹105.08 |
| Metric | Edelweiss NAV ₹24.13 Very High risk ★★☆☆☆ 1Y | Category median Other ETFs · 73 funds |
|---|---|---|
| +2.00% | +4.04% | |
| — | +10.87% | |
| — | +9.30% | |
| — | +11.96% | |
| +9.35% | +11.34% | |
| +8.19% | — | |
| — | +14.16% | |
| — | +14.63% | |
| — | +13.16% | |
| Risk | ||
| 19.40% | 14.74% | |
| -0.23 | 0.30 | |
| -0.33 | 0.42 | |
| -17.55% | -21.01% | |
| Nifty 500 | — | |
| — | +0.59% | |
| — | 1.00 | |
| — | 100.9% | |
| — | 97.8% | |
| 0.58% | 0.29% | |
| ₹15.56Cr | ₹143.12Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Bhavesh Jain | — | |
| 31 Dec 2024 | — | |
| 26 | — | |
| 67.0% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.